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Introduction
I
n recent decades, research has identified the 
podocyte as a major player in the patho­
physiology of proteinuric glomerular diseases 
(Figure 1). The great interest in podocyte 
biology was reflected by the large number of 
participants at the 9th International Podocyte 
Conference, held in Miami in April 2012. At this 
biannual conference, speakers and discussants 
from all over the world highlighted recent find­
ings and advances in podocyte research with a 
particular focus on translating this biology into 
potential therapeutic approaches to podocyto­
pathies and glomerular diseases. The themes 
discussed in depth included systems biology 
approaches to understanding and classifying glo­
merular diseases; the role of the podocyte actin 
cytoskeleton in proteinuric disease; new aspects 
of slit diaphragm function; novel discoveries of 
disease­causing gene mutations by next­gener­
ation sequencing; in vivo imaging techniques to 
study glomerular dynamics; and insights into 
podocyte regeneration. We provide here a brief 
summary of exciting new developments, which 
unfortunately cannot be all­inclusive.
The ‘-omics’ era approaches the glomerulus
The field of systems biology was covered by a 
whole session, which illustrated that this approach 
will certainly play an important role in improving 
our understanding of the podocyte. One example 
of such an approach is PodNet, by K. Endlich. The 
PodNet program is a putative protein–protein 
network using bioinformatics algorithms to gen­
erate possible signaling and protein interaction 
networks for the podocyte. PodNet and several 
other recently started systems biology initiatives 
on podocytes will certainly help to integrate the 
complex information gained by genomic and pro­
teomic screening.
Aside from transcriptome and proteome 
analysis, the field of epigenetics is approach­
ing podocyte biology. Reversible modifications 
of the structure of DNA exhibit the next level of 
possible regulatory pathways. K. Susztak presented 
data on human diabetic kidney samples, which 
underlined that epigenetic modification might 
contribute to the development of diabetic kidney 
disease. To define causative effects in the observed 
modifications and separate them from simple 
bystander effects will be an important task for 
future research, as Susztak stated. In a panel dis­
cussion, the question of how to correlate ‘­omics’ 
results with pathology and clinical presentation 
was debated, and the need for standardized and 
digitalized pathology procedures was emphasized.
The subject of how to combine state­of­the­
art genetic testing, classification of rare diseases, 
and standardization of treatment studies was 
addressed by M. Kretzler of the multicenter 
Nephrotic Syndrome Study Network (Neptune). 
This unique platform will probably not only play 
an important role in identifying new possible 
pathomechanisms in steroid­resistant nephrotic 
syndrome, but furthermore might act as a key 
tool in developing and validating new therapeu­
tic approaches.
Old friends, but still major players: the actin 
cytoskeleton and integrins
The actin cytoskeleton and the integrin system 
were covered in several sessions, and although 
these topics appear to be quite well established in 
the field, interesting novel work was presented. 
S. Ishibe introduced his talk with the statement 
“Podocytes stuck in traffic?” and demonstrated 
the vital importance of the elaborated endocytic 
machinery that is closely linked to the podocyte 
actin cytoskeleton. T. Fujita demonstrated the 
interconnections between the Rac1 system and 
the mineralocorticoid receptor, which have finally 
led to the identification of possible drug targets. 
S. Sever summarized the importance of the actin 
cytoskeleton with the provocative statement 
that actin overcomes genomics, because most 
mutations or injury mechanisms finally result 
in rearrangement of actin fibers, podocyte foot 
process effacement, and proteinuria. Therefore, a 
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therapeutic targeting and stabilization of the podo­
cyte actin cytoskeleton could potentially be used 
for a broad range of genetic and acquired podo­
cytopathies. As an example, Sever presented data 
on the use of dynamin stabilization to secure the 
podocyte cytoskeleton from injury in cellular and 
animal models.
The slit diaphragm, an evolving platform
That the slit diaphragm is not just a simple sieve 
but rather a complex signaling platform is not 
news to the field. Nevertheless, novel concepts 
were presented when L. Sellin showed data on new 
endocytic mechanisms of nephrin, which might 
also play a role in certain disease states, such as 
diabetic nephropathy. M. Schiffer demonstrated 
the impact of CD2AP on its paralog CIN85 in 
terms of post­translational modification and 
provided one more example of the complex and 
dynamic interplay of slit diaphragm­associated 
proteins. T. Huber illustrated the advantage of 
using suitable model organisms to delineate the 
functions of Neph and nephrin proteins. This was 
exemplified by the Caenorhabditis elegans model, 
in which nephrin/Neph1 orthologs specify synap­
tic connectivity between epithelial guidepost cells 
and neurons, and the Drosophila nephrocyte sys­
tem, in which nephrin/Neph1 orthologs assemble 
a slit diaphragm­like cell contact.
New techniques in the field: a closer look at 
the podocyte by exome sequencing and in vivo 
multiphoton imaging
M. Pollak and F. Hildebrandt presented data on 
very recent and partially unpublished discover­
ies on hereditary podocyte diseases. Using next­
generation exome sequencing, Hildebrandt and 
his co­workers were able to identify new causative 
genes for steroid­resistant nephrotic syndrome 
that are interconnected with the RhoA pathway, 
underlining the delicate involvement of Rho­
GTPase modulation in podocyte homeostasis. As 
the cost of sequencing approaches steadily drops 
and methods get faster, several further gene dis­
coveries to be expected within the next few years 
will fundamentally contribute to our understand­
ing of podocyte biology and disease.
Another innovative field is the application of 
in vivo multiphoton imaging of the glomerulus. 
Fascinating images were presented by B. Molito­
ris and J. Peti­Peterdi. The newly developed tech­
nique of Peti­Peterdi’s laboratory for following the 
same glomerulus over periods of several days in 
an in vivo imaging setting will allow novel insights 
into glomerular dynamics.
Glomerular regeneration: is there hope for the 
damaged podocyte?
A whole session was devoted to the field of 
glomerular regeneration. Are stem cells really 
capable of preventing podocyte loss or even 
contributing to regeneration? So far, parietal 
epithelial cells are generally accepted as a poten­
tial stem­cell niche for podocytes. S. Shankland 
provided new data on a possible additional cell 
type, also involved in podocyte regeneration, a 
cell population that expresses renin under physi­
ological conditions. Although his findings are 
rather preliminary, as he stated, the presented 
data appear to provide a promising new candidate 
in the riddle of possible podocyte regeneration.
R. Kalluri introduced another concept regard­
ing podocyte regeneration in proposing fusion 
events between stem cells and damaged podo­
cytes, which appear to involve the podocyte 
cytoskeleton. This session highlighted once more 
the enormous interest in possible mechanisms of 
glomerular regeneration and the need for further 
research to identify ways for therapeutic interven­
tions to enhance podocyte regeneration.
New pathways of proteinuria
In recent years, several groups have identified new 
pathways for various proteinuric glomerular dis­
eases. S. Chugh provided new data on the concept 
of angiopoietin­like 4­mediated development of 
Figure 1 | Confocal image of double-transgenic fluorescent mice illustrates the 
fascinating podocyte foot process network in vivo. 
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minimal­change disease; D. Salant reported new 
insights about possible pathogenetic pathways in 
membranous nephropathy involving PLA2 recep­
tor antibodies and the complement system; and 
C. Wei, colleague of the conference’s host organ­
izer, J. Reiser, presented new clinical data on 
soluble urokinase plasminogen activator recep­
tor (suPAR) as a circulating permeability factor 
in focal segmental glomerulosclerosis. Finally, 
D. Kerjaschki introduced a new class of player, 
microRNAs, as potential important instigators of 
podocytopathy.
Where is the field heading?
Podocyte research has reached a ‘tipping point’—
not only in implementing innovative and state­
of­the­art methods, but also in identifying new 
therapeutic targets. Although there is still a tough 
road ahead of us, this meeting identified several 
avenues for successful translation of research into 
novel podocyte­targeted therapies for primary 
proteinuric glomerular diseases.
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